keyword
MENU ▼
Read by QxMD icon Read
search

Ankylosing spondyloarthritis

keyword
https://www.readbyqxmd.com/read/28724442/impact-of-obesity-on-the-response-to-tumor-necrosis-factor-inhibitors-in-axial-spondyloarthritis
#1
Raphael Micheroli, Monika Hebeisen, Lukas M Wildi, Pascale Exer, Giorgio Tamborrini, Jürg Bernhard, Burkhard Möller, Pascal Zufferey, Michael J Nissen, Almut Scherer, Adrian Ciurea
BACKGROUND: Few studies have investigated the impact of obesity on the response to tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). The aim of our study was to investigate the impact of different body mass index (BMI) categories on TNFi response in a large cohort of patients with axSpA. METHODS: Patients with axSpA within the Swiss Clinical Quality Management (SCQM) program were included in the current study if they fulfilled the Assessment in Spondyloarthritis International Society (ASAS) criteria for axSpA, started a first TNFi after recruitment, and had available BMI data as well as a baseline and follow-up visit at 1 year (±6 months)...
July 19, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28723711/epidemiology-of-autoimmune-and-inflammatory-diseases-in-a-french-nationwide-hiv-cohort
#2
D Lebrun, M Hentzien, L Cuzin, D Rey, V Joly, L Cotte, C Allavena, P Dellamonica, A Servettaz, F Bani-Sadr
HIV infection and inflammatory and autoimmune diseases (IAD) are both related to immune dysfunction. Epidemiological data on IAD in patients living with HIV (PLHIV) are scarce. The aim of this study was thus to estimate the prevalence of 26 IAD among PLHIV followed in a large French multicenter cohort in the cART era (from January 2000 to July 2013), and to describe their occurrence according to cART onset, the immuno-virological status of patients and HCV and/or HBV co-infection.During the study period, 33 403 PLHIV were included in the Dat'AIDS cohort; 1381 patients with an IAD were identified...
July 18, 2017: AIDS
https://www.readbyqxmd.com/read/28718336/coexistence-of-takayasu-s-arteritis-and-ankylosing-spondylitis-may-not-be-accidental-is-there-a-need-for-a-new-subgroup-in-the-spondyloarthritis-family
#3
Pawel Mielnik, Anja Myhre Hjelle, Jan Leidulv Nordeide
Aortitis of ascending aorta is a recognized complication of ankylosing spondylitis (AS). There are a few published cases of diffuse aortitis and aorta collaterals inflammation that fulfill Takayasu's arteritis (TA) criteria coexisting with AS. We have reviewed published cases from literature and present three new cases of such coexistence. We identified three patients who fulfilled definite AS New York criteria in our Takayasu's vasculitis cohort of eight patients. One of this patients had been diagnosed with Crohn's disease before AS and TA diagnosis...
July 18, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28698330/clinical-characteristics-of-importance-to-outcome-in-patients-with-axial-spondyloarthritis-protocol-for-a-prospective-descriptive-and-exploratory-cohort-study
#4
Rikke Asmussen Andreasen, Lars Erik Kristensen, Torkell Ellingsen, Robin Christensen, Xenofon Baraliakos, Jimmi Wied, Claus Aalykke, Thomas Ulstrup, Berit Schiøttz-Christensen, Hans Christian Horn, Amir Emamifar, Bent Duerlund, Lars Fischer, Inger Marie Jensen Hansen
INTRODUCTION: Spondyloarthritis (SpA) is a heterogeneous spectrum of rheumatic diseases with either predominantly axial inflammatory symptoms of the spine and sacroiliac joints or predominantly peripheral arthritis. The two main entities of axial SpA (axSpA) are ankylosing spondylitis or non-radiographic axSpA (nr-axSpA). Tumour necrosis factor-α inhibitors have revolutionised the treatment of patients with axSpA who failed to respond to non-steroidal anti-inflammatory drugs and physical therapy...
July 10, 2017: BMJ Open
https://www.readbyqxmd.com/read/28684559/treating-axial-spondyloarthritis-and-peripheral-spondyloarthritis-especially-psoriatic-arthritis-to-target-2017-update-of-recommendations-by-an-international-task-force
#5
Josef S Smolen, Monika Schöls, Jürgen Braun, Maxime Dougados, Oliver FitzGerald, Dafna D Gladman, Arthur Kavanaugh, Robert Landewé, Philip Mease, Joachim Sieper, Tanja Stamm, Maarten de Wit, Daniel Aletaha, Xenofon Baraliakos, Neil Betteridge, Filip van den Bosch, Laura C Coates, Paul Emery, Lianne S Gensler, Laure Gossec, Philip Helliwell, Merryn Jongkees, Tore K Kvien, Robert D Inman, Iain B McInnes, Mara Maccarone, Pedro M Machado, Anna Molto, Alexis Ogdie, Denis Poddubnyy, Christopher Ritchlin, Martin Rudwaleit, Adrian Tanew, Bing Thio, Douglas Veale, Kurt de Vlam, Désirée van der Heijde
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item...
July 6, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28682112/etanercept-for-treating-axial-spondyloarthritis
#6
Xavier Guillot, Clément Prati, Maxime Sondag, Daniel Wendling
Axial spondyloarthritis is an inflammatory rheumatic disease causing back pain, functional impairment and potential ankylosis in the advanced stage. In this context, TNF blockers have been a major therapeutic advance. Etanercept is a soluble recombinant TNF receptor fusion protein in this vain. Areas covered: The aim of this review is to summarize the current published data concerning the efficacy and tolerance of etanercept in axial spondyloarthrits. The authors performed a systematic review on PubMed, using 'etanercept' and 'spondyloarthritis', 'axial spondyloarthritis' or 'ankylosing spondylitis' keywords...
July 6, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28661926/the-discriminative-values-of-the-bath-ankylosing-spondylitis-disease-activity-index-ankylosing-spondylitis-disease-activity-score-c-reactive-protein-and-erythrocyte-sedimentation-rate-in-spondyloarthritis-related-axial-arthritis
#7
Helen Hoi Lun Tsang, Ho Yin Chung
OBJECTIVES: The aims of this study were to determine the effectiveness of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP), Ankylosing Spondylitis Disease Activity Score-Erythrocyte Sedimentation Rate (ASDAS-ESR), and inflammatory markers in screening for axial-joint inflammation as detected by magnetic resonance imaging (MRI) and to find out factors that could affect scoring of the indices. METHODS: One hundred fifty-three Chinese spondyloarthritis patients were recruited...
June 29, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28649913/faecal-calprotectin-detects-subclinical-bowel-inflammation-and-may-predict-treatment-response-in-spondyloarthritis
#8
R D Østgård, B W Deleuran, M Y Dam, I T Hansen, A G Jurik, H Glerup
OBJECTIVE: Intestinal inflammation is frequent in patients with spondyloarthritis (SpA). Here, we test the validity of faecal calprotectin as a marker of intestinal inflammation in SpA patients and evaluate the response of adalimumab in patients with and without intestinal lesions. METHOD: Patients were included on the basis of active SpA with a Bath Ankylosing Spondylitis Disease Activity Index ≥ 4. After a 4 week non-steroidal anti-inflammatory drug washout period, patients were divided into two groups based on faecal calprotectin level (> 100 mg/kg, n = 15, and < 50 mg/kg, n = 15)...
June 26, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28638241/oral-anaerobic-bacteria-in-the-etiology-of-ankylosing-spondylitis
#9
REVIEW
Mesut Öğrendik
Ankylosing spondylitis (AS) is associated with periodontitis. Anti-Porphyromonas gingivalis and anti-Prevotella intermedia antibody titers were higher in patients with spondyloarthritis than in healthy people. Sulfasalazine is an effective antibiotic treatment for AS. Moxifloxacin and rifamycin were also found to be significantly effective. The etiology hypothesis suggests that oral anaerobic bacteria such as Porphyromonas spp and Prevotella spp contribute to the disease. These bacteria have been identified in AS, and we will discuss their pathogenic properties with respect to our knowledge of the disease...
2017: Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28631696/-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-two-stages-of-disease
#10
D G Rumyantseva, T V Dubinina, A B Demina, O A Rumyantseva, E M Agafonova, A V Smirnov, Sh F Erdes
AIM: To compare the clinical manifestations of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nrAxSpA). SUBJECTS AND METHODS: A Moscow early spondyloarthritis cohort has now included 132 patients with axial spondyloarthritis, of whom 69 patients who have been followed up at least 12 months are to be involved in a preliminary analysis. The mean age at the time of inclusion in the study was 28.1±5.5 years; the mean disease duration was 24...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28630526/discriminating-value-of-calprotectin-in-disease-activity-and-progression-of-nonradiographic-axial-spondyloarthritis-and-ankylosing-spondylitis
#11
Jinxian Huang, Zhihua Yin, Guoxiang Song, Shengjin Cui, Jinzhao Jiang, Lijun Zhang
It has been controversial whether ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpA) are separate or different phases of radiographic progression. We determined that serum calprotectin level (ng/ml) was higher in AS (15.30 ± 6.49) and nr-axSpA (17.76 ± 8.59) patients than in healthy individuals (7.40 ± 2.67). No difference was observed in calprotectin level between these two groups. Elevated calprotectin was positively correlated with ESR, CRP, BASDAI, and ASDAS as well as SPARCC scoring and had no correlation with BASFI and mSASSS...
2017: Disease Markers
https://www.readbyqxmd.com/read/28629905/2017-american-college-of-rheumatology-american-association-of-hip-and-knee-surgeons-guideline-for-the-perioperative-management-of-antirheumatic-medication-in-patients-with-rheumatic-diseases-undergoing-elective-total-hip-or-total-knee-arthroplasty
#12
Susan M Goodman, Bryan Springer, Gordon Guyatt, Matthew P Abdel, Vinod Dasa, Michael George, Ora Gewurz-Singer, Jon T Giles, Beverly Johnson, Steve Lee, Lisa A Mandl, Michael A Mont, Peter Sculco, Scott Sporer, Louis Stryker, Marat Turgunbaev, Barry Brause, Antonia F Chen, Jeremy Gililland, Mark Goodman, Arlene Hurley-Rosenblatt, Kyriakos Kirou, Elena Losina, Ronald MacKenzie, Kaleb Michaud, Ted Mikuls, Linda Russell, Alexander Sah, Amy S Miller, Jasvinder A Singh, Adolph Yates
OBJECTIVE: This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA)...
June 16, 2017: Journal of Arthroplasty
https://www.readbyqxmd.com/read/28624373/acute-tubulointerstitial-nephritis-in-an-hla-b27-positive-patient-with-axial-spondyloarthritis-being-treated-with-adalimumab
#13
David Castro Corredor, María Dolores Sánchez de la Nieta, Isabel María de Lara Simón
Antagonists of tumor necrosis factor-alpha (ATNF) are used for the treatment of multiple diseases such as psoriatic arthritis, Crohn's disease, ankylosing spondylitis and juvenile idiopathic arthritis, usually, when they are refractory to first-line treatment(1). The use of ATNF has been associated with the induction of autoimmune diseases such as systemic lupus erythematosus-like disease, vasculitis, sarcoidosis-like diseases and, recently, acute granulomatous tubulointerstitial nephritis. We report a case of acute nongranulomatous tubulointerstitial nephritis in an HLA-B27-positive patient with axial spondyloarthritis and Crohn's disease being treated with adalimumab...
June 14, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28623950/work-outcome-in-yet-undiagnosed-patients-with-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis-results-of-a-cross-sectional-study-among-patients-with-chronic-low-back-pain
#14
Lonneke van Hoeven, Annelies E R C H Boonen, Johanna M W Hazes, Angelique E A M Weel
BACKGROUND: To understand the impact of yet undiagnosed non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) on work outcomes in a cohort of patients with long-lasting chronic low back pain (CLBP). METHODS: Data were used from a primary care CLBP cohort that was established to understand the prevalence of nr-axSpA and AS. Clinical characteristics comprised measures of back pain (visual analogue scale), inflammation (C-reactive protein) and physical functioning (Roland Morris Disability Questionnaire (RMDQ))...
June 17, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28622461/the-co-occurrence-and-characteristics-of-patients-with-axial-spondyloarthritis-who-meet-criteria-for-fibromyalgia-results-from-a-uk-national-register-bsrbr-as
#15
Gary J Macfarlane, Maxwell S Barnish, Ejaz Pathan, Kathryn R Martin, Kirstie L Haywood, Stefan Siebert, Jonathan Packham, Fabiola Atzeni, Gareth T Jones
OBJECTIVE: To estimate the proportion of patients with axial spondyloarthritis (axSpA) who meet criteria for fibromyalgia (FM) and to characterise such patients. METHODS: The British Society for Rheumatology Biologics Register of Ankylosing Spondylitis (BSRBR-AS) recruits two cohorts of patients who meet ASAS criteria for axSpA across 83 centres in the United Kingdom. Patients are either newly starting (biologic cohort) or naïve (non-biologic cohort) to biologic therapy and are followed prospectively...
June 16, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28620948/2017-american-college-of-rheumatology-american-association-of-hip-and-knee-surgeons-guideline-for-the-perioperative-management-of-antirheumatic-medication-in-patients-with-rheumatic-diseases-undergoing-elective-total-hip-or-total-knee-arthroplasty
#16
Susan M Goodman, Bryan Springer, Gordon Guyatt, Matthew P Abdel, Vinod Dasa, Michael George, Ora Gewurz-Singer, Jon T Giles, Beverly Johnson, Steve Lee, Lisa A Mandl, Michael A Mont, Peter Sculco, Scott Sporer, Louis Stryker, Marat Turgunbaev, Barry Brause, Antonia F Chen, Jeremy Gililland, Mark Goodman, Arlene Hurley-Rosenblatt, Kyriakos Kirou, Elena Losina, Ronald MacKenzie, Kaleb Michaud, Ted Mikuls, Linda Russell, Alexander Sah, Amy S Miller, Jasvinder A Singh, Adolph Yates
OBJECTIVE: This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA)...
June 16, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28620917/2017-american-college-of-rheumatology-american-association-of-hip-and-knee-surgeons-guideline-for-the-perioperative-management-of-antirheumatic-medication-in-patients-with-rheumatic-diseases-undergoing-elective-total-hip-or-total-knee-arthroplasty
#17
Susan M Goodman, Bryan Springer, Gordon Guyatt, Matthew P Abdel, Vinod Dasa, Michael George, Ora Gewurz-Singer, Jon T Giles, Beverly Johnson, Steve Lee, Lisa A Mandl, Michael A Mont, Peter Sculco, Scott Sporer, Louis Stryker, Marat Turgunbaev, Barry Brause, Antonia F Chen, Jeremy Gililland, Mark Goodman, Arlene Hurley-Rosenblatt, Kyriakos Kirou, Elena Losina, Ronald MacKenzie, Kaleb Michaud, Ted Mikuls, Linda Russell, Alexander Sah, Amy S Miller, Jasvinder A Singh, Adolph Yates
OBJECTIVE: This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA)...
June 16, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28612240/clinical-characteristics-of-peripheral-spondyloarthritis-without-psoriasis-inflammatory-enteropathy-or-preceding-infection-from-a-single-rheumatology-clinic-in-northern-india
#18
Anand Narayan Malaviya, Neha Agrawal, Nilesh Sahebrao Patil
The objective of this study was to characterise the peripheral arthritis of spondyloarthritis (pSpA) excluding psoriatic-, inflammatory enteropathy-related, post-infectious reactive-SpA and arthritis associated with axial SpA/ankylosing spondylitis (axSpA/AS). Patients presenting with the clinical features of the broad spectrum of SpA were screened for the presence of peripheral arthritis using the Assessment of SpondyloArthritis International Society (ASAS) criteria. The other conditions that could cause pSpA, e...
June 13, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28612180/immunogenicity-of-biologics-in-chronic-inflammatory-diseases-a-systematic-review
#19
REVIEW
Vibeke Strand, Alejandro Balsa, Jamal Al-Saleh, Leonor Barile-Fabris, Takahiko Horiuchi, Tsutomu Takeuchi, Sadiq Lula, Charles Hawes, Blerina Kola, Lisa Marshall
OBJECTIVES: A systematic review was conducted to explore the immunogenicity of biologic agents across inflammatory diseases and its potential impact on efficacy/safety. METHODS: Literature searches were conducted through November 2016 to identify controlled and observational studies of biologics/biosimilars administered for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), psoriasis (Ps), Crohn's disease, and ulcerative colitis...
June 13, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28575536/valuing-treatment-with-infliximab-for-ankylosing-spondylitis-using-a-willingness-to-pay-approach
#20
Casper Webers, Ivette Essers, Astrid van Tubergen, Jürgen Braun, Frank Heldmann, Xenofon Baraliakos, Annelies Boonen
OBJECTIVE: To investigate willingness to pay (WTP) for treatment with infliximab by patients with ankylosing spondylitis (AS) and explore factors associated with WTP. METHODS: Data were used from 85 patients participating in the European AS Infliximab Cohort (EASIC) open-label extension of the AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT). WTP was included at baseline of EASIC and comprised a hypothetical scenario exploring whether the patient would be willing to pay for beneficial effects of infliximab and, if so, what amount they would be willing to pay per administration...
June 2, 2017: Arthritis Care & Research
keyword
keyword
100428
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"